Improved long-term biocompatibility of coronary stents by plasma coating process

Improved long term biocompatibility of coronary stents by plasma coating process Abstract Drug eluting stentsDEShave been widely used to treat patients of coronary heart diseaseCHDdue to their better ability to control restenosis than bare metal stentsBMSHoweverthere is a high risk of late in stent thrombosis associated with DES after implantation in patientswhich could lead to fatal heart attack and death even though it occurs at low rateThusfor safe and effective clinical usea coronary stent needs to have better long term biocompatibility on its surface that will provide sufficient thrombo resistance in addition to inhibiting smooth muscle cell proliferation thereby slowing down healing of tissues around the stentNanovaIncis developing a novel coating layer of high thrombo resistance on the surface of stents made of stainless steel or CrCoAn environmentally benign technologylow temperature plasma process is used to deposit an ultra thinnano scalebut continuous layer of coatingsufficient to generate desired abrasion resistance and immobilize the bioactive functional groups created in the subsequent surface treatment to prevent blood clotting and restenosisbut thin enough to allow for stent expansion without cracking when delivered into the atherosclerotic coronary arteries of patientsThe knowledge gained in this innovative research project will also benefit research and development for improved biocompatibility for other implantable medical devices such as pacemakerspulse generatorscardiac defibrillators and bio sensors NanovaIncis developing and commercializing a novel nanocoating technology for application to coronary stents to prevent both restenosisre narrowingof coronary arteries and late in stent thrombosisblood clots in stentsfor safer and more effective treatment of coronary heart diseasewhich will benefit over one million of patients in the United States